Ligand compounds, conjugates, and applications thereof

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that comprise one or more ligand moieties for an asialoglycoprotein receptor (ASGPR). Exemplary chemical entities can further...

Full description

Saved in:
Bibliographic Details
Main Authors ZHAO, Haoting, ZHANG, Bill Biliang
Format Patent
LanguageEnglish
Published 29.02.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that comprise one or more ligand moieties for an asialoglycoprotein receptor (ASGPR). Exemplary chemical entities can further comprise an oligonucleotide. Said chemical entities are useful, e.g., in the targeted delivery of oligonucleotides to liver cells (e.g., liver parenchymal cells). The chemical entities are useful e.g., in the treatment of conditions or diseases caused by the expression (e.g., abnormal expression) of one or more genes in liver cells This disclosure also features compositions containing the same as well as methods of using and making the same.
AbstractList This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that comprise one or more ligand moieties for an asialoglycoprotein receptor (ASGPR). Exemplary chemical entities can further comprise an oligonucleotide. Said chemical entities are useful, e.g., in the targeted delivery of oligonucleotides to liver cells (e.g., liver parenchymal cells). The chemical entities are useful e.g., in the treatment of conditions or diseases caused by the expression (e.g., abnormal expression) of one or more genes in liver cells This disclosure also features compositions containing the same as well as methods of using and making the same.
Author ZHAO, Haoting
ZHANG, Bill Biliang
Author_xml – fullname: ZHAO, Haoting
– fullname: ZHANG, Bill Biliang
BookMark eNrjYmDJy89L5WQw88lMT8xLUUjOzy3IL81LKdYBMvOyStMTS1KBbJBUYkFBTmZyYklmfl6xQklGalFqfhoPA2taYk5xKi-U5mZQcXMNcfbQTS3Ij08tLkhMTs1LLYl3DDUyMDI0MTI0NDN0cjIyJlIZALchMJY
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID AU2021421161BB2
GroupedDBID EVB
ID FETCH-epo_espacenet_AU2021421161BB23
IEDL.DBID EVB
IngestDate Fri Aug 02 08:55:54 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_AU2021421161BB23
Notes Application Number: AU20210421161
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240229&DB=EPODOC&CC=AU&NR=2021421161B2
ParticipantIDs epo_espacenet_AU2021421161BB2
PublicationCentury 2000
PublicationDate 20240229
PublicationDateYYYYMMDD 2024-02-29
PublicationDate_xml – month: 02
  year: 2024
  text: 20240229
  day: 29
PublicationDecade 2020
PublicationYear 2024
RelatedCompanies ARGORNA PHARMACEUTICALS CO., LTD
RelatedCompanies_xml – name: ARGORNA PHARMACEUTICALS CO., LTD
Score 3.523761
Snippet This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
DERIVATIVES THEREOF
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SUGARS
Title Ligand compounds, conjugates, and applications thereof
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240229&DB=EPODOC&locale=&CC=AU&NR=2021421161B2
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3dS8MwED_GFPVNp-LXpA-jTxbbru2ShyH2iyHuA9lkb6NpE5lIO2yH_76X0Gmf9O2SgyMJXO5-d7kLQK9vUzNDaGVkxE4QoFDXIBmjhjUwE4sLIdJExiHHE2-0cJ6W7rIFH7taGNUn9Es1R0SNSlHfK3Vfb36DWKF6W1neszVOFQ_xfBjqNTqWqQIE0KE_jGbTcBroQYBIUp-8SJ7lINjxLB8v7D3pSMtO-9GrL-tSNk2jEh_D_gzl5dUJtHjegcNg9_daBw7GdcobyVr7ylPwntdvCPw1-Qxc_oZU3iGZv29lJAxpyWrmozXp2_FCnEEvjubByMAFrH72u3pcNFbr2_1zaOdFzi9Ay9B_ICkbEMqJ02ckMV0cCVcwhxGX0kvo_inq6h_-NRzJQ1Ql2_QG2tXnlnfR6FbsVp3VN1ZVhL8
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3dS8MwED_GFOebTsWp0z6MPlls16_kYYhtV6pu3ZBO9jaafshE2mE7_Pe9lE77pG-XHBxJ4HL3u8tdAAbqkMoxQispJsMQAQrVJRIzKimmHCpJmqZRyOOQU9_wFtrTUl-24GNXC1P1Cf2qmiOiRkWo72V1X29-g1hO9bayuGNrnMrv3WDkiDU65qkCBNCONRrPZ87MFm0bkaTov3CeoiHYMRQLL-w9k_fn5c7Tq8XrUjZNo-Iewf4c5WXlMbSSrAsde_f3WhcOpnXKG8la-4oTMCbrNwT-An8Gzn9DKm6RzN63PBKGNGc189EC9-2SPD2FgTsObE_CBax-9rt6WDRWaw3VM2hneZacgxCj_0AiZhKaEE1lJJR1HKV6yjRGdEp70P9T1MU__BvoeMF0spo8-s-XcMgPtCrfplfQLj-3SR8NcMmuq3P7BrQAh6w
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Ligand+compounds%2C+conjugates%2C+and+applications+thereof&rft.inventor=ZHAO%2C+Haoting&rft.inventor=ZHANG%2C+Bill+Biliang&rft.date=2024-02-29&rft.externalDBID=B2&rft.externalDocID=AU2021421161BB2